Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published on October 12, 2021 in New York, NY
October 12th, 2021 – New York - Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), to be held in Washington, D.C. and virtually on November 10 to 14, 2021.
Cellectis will present a poster on UCARTMESO, an allogeneic CAR-T cell product candidate targeting mesothelin - expressing solid tumors. Mesothelin is a tumor-associated antigen that is highly and consistently expressed in mesothelioma and pancreatic cancer and is also over-expressed in subsets of other solid tumors (ovarian cancer, non-small cell lung cancer, gastric cancer, triple-negative breast cancer). UCARTMESO also leverages its TALEN® gene editing technology to resist immune suppression mediated by TGFβ.
Last May, during its Innovation Days, Cellectis announced the development of the new pre-clinical UCART product candidates targeting B-cell lymphomas and venturing for the first time into the solid tumor space.
Title: Mesothelin (MSLN) targeting allogeneic CAR-T cells engineered to overcome tumor immunosuppressive microenvironment
Poster Number: 143
Presenter: Roman Galetto, Ph.D, Director, Preclinical and Program Management
Date/Time: Friday November 12, 7:00AM - 8:30PM, Walter E. Washington Convention Center, Poster Hall (Hall E)
Full text of the abstracts will be released on the SITC website at 7:00 a.m. ET on November 12, 2021.